Alzinova AB (publ) (ALZ.ST)
SEK 2.02
(1.46%)
SEK 2.02
(1.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.48 Million SEK | -26.09% |
| 2022 | -13.06 Million SEK | -72.32% |
| 2021 | -7.58 Million SEK | -16.68% |
| 2020 | -6.5 Million SEK | -4.81% |
| 2019 | -6.2 Million SEK | -48.05% |
| 2018 | -4.18 Million SEK | -67.03% |
| 2017 | -2.5 Million SEK | 15.38% |
| 2016 | -2.96 Million SEK | 13.01% |
| 2015 | -3.4 Million SEK | -622.63% |
| 2014 | -471.51 Thousand SEK | -40.44% |
| 2013 | -335.72 Thousand SEK | 81.9% |
| 2012 | -1.85 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.96 Million SEK | -4.9% |
| 2024 Q2 | -4.87 Million SEK | 1.75% |
| 2023 Q2 | -3.92 Million SEK | 8.02% |
| 2023 Q4 | -4.73 Million SEK | -33.31% |
| 2023 Q1 | -4.27 Million SEK | 9.46% |
| 2023 FY | -16.48 Million SEK | -26.09% |
| 2023 Q3 | -3.54 Million SEK | 9.66% |
| 2022 Q4 | -4.71 Million SEK | -70.21% |
| 2022 Q3 | -2.77 Million SEK | 16.01% |
| 2022 FY | -13.06 Million SEK | -72.32% |
| 2022 Q2 | -3.29 Million SEK | -44.58% |
| 2022 Q1 | -2.28 Million SEK | 7.06% |
| 2021 Q3 | -1.45 Million SEK | 33.25% |
| 2021 FY | -7.58 Million SEK | -16.68% |
| 2021 Q1 | -1.46 Million SEK | 38.11% |
| 2021 Q2 | -2.17 Million SEK | -49.19% |
| 2021 Q4 | -2.45 Million SEK | -68.76% |
| 2020 Q2 | -1.12 Million SEK | 36.7% |
| 2020 FY | -6.5 Million SEK | -4.81% |
| 2020 Q4 | -2.36 Million SEK | -90.4% |
| 2020 Q3 | -1.24 Million SEK | -10.38% |
| 2020 Q1 | -1.77 Million SEK | 37.6% |
| 2019 Q1 | -1.17 Million SEK | 45.09% |
| 2019 Q4 | -2.84 Million SEK | -367.8% |
| 2019 Q2 | -1.56 Million SEK | -33.87% |
| 2019 Q3 | -608.01 Thousand SEK | 61.2% |
| 2019 FY | -6.2 Million SEK | -48.05% |
| 2018 Q2 | -740.89 Thousand SEK | 13.45% |
| 2018 Q1 | -855.99 Thousand SEK | 9.19% |
| 2018 FY | -4.18 Million SEK | -67.03% |
| 2018 Q4 | -2.13 Million SEK | -363.0% |
| 2018 Q3 | -460.46 Thousand SEK | 37.85% |
| 2017 Q3 | -137.08 Thousand SEK | 74.99% |
| 2017 Q2 | -548.1 Thousand SEK | 37.73% |
| 2017 Q1 | -880.25 Thousand SEK | 39.55% |
| 2017 FY | -2.5 Million SEK | 15.38% |
| 2017 Q4 | -942.66 Thousand SEK | -587.68% |
| 2016 Q2 | -689.57 Thousand SEK | -146.12% |
| 2016 Q4 | -1.45 Million SEK | -170.66% |
| 2016 Q1 | -280.17 Thousand SEK | 87.01% |
| 2016 FY | -2.96 Million SEK | 13.01% |
| 2016 Q3 | -538.03 Thousand SEK | 21.98% |
| 2015 Q4 | -2.15 Million SEK | -313.34% |
| 2015 Q1 | -263.51 Thousand SEK | -434.16% |
| 2015 FY | -3.4 Million SEK | -622.63% |
| 2015 Q3 | -521.68 Thousand SEK | -12.01% |
| 2015 Q2 | -465.73 Thousand SEK | -76.74% |
| 2014 FY | -471.51 Thousand SEK | -40.44% |
| 2014 Q4 | -49.33 Thousand SEK | 0.0% |
| 2013 FY | -335.72 Thousand SEK | 81.9% |
| 2012 FY | -1.85 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 64.017% |
| Biovica International AB (publ) | -124.82 Million SEK | 86.797% |
| Cantargia AB (publ) | -280.02 Million SEK | 94.115% |
| CombiGene AB (publ) | -35.66 Million SEK | 53.793% |
| Cyxone AB (publ) | -22.98 Million SEK | 28.314% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -41.12% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -0.5% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 81.97% |
| Fluicell AB (publ) | -26.55 Million SEK | 37.938% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 86.609% |
| Mendus AB (publ) | -101.61 Million SEK | 83.783% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 55.545% |
| I-Tech AB | 20.2 Million SEK | 181.572% |
| Intervacc AB (publ) | -102.85 Million SEK | 83.977% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -35.884% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 235.426% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 7.918% |
| OncoZenge AB (publ) | -15.9 Million SEK | -3.635% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3662.557% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.754% |
| Lipum AB (publ) | -37.17 Million SEK | 55.673% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 93.371% |
| Ziccum AB (publ) | -21.41 Million SEK | 23.034% |
| BioArctic AB (publ) | 229.24 Million SEK | 107.189% |
| Genovis AB (publ.) | 61.5 Million SEK | 126.797% |
| Camurus AB (publ) | 431.44 Million SEK | 103.82% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 90.733% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 70.997% |
| Aptahem AB (publ) | -11.11 Million SEK | -48.297% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.7% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 90.827% |
| Kancera AB (publ) | -64.88 Million SEK | 74.603% |
| Saniona AB (publ) | -95.81 Million SEK | 82.799% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 60.969% |
| AcouSort AB (publ) | -17.08 Million SEK | 3.564% |
| Xintela AB (publ) | -54.08 Million SEK | 69.528% |
| Abliva AB (publ) | -95.5 Million SEK | 82.745% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 405.978% |
| Amniotics AB (publ) | -30.87 Million SEK | 46.615% |
| 2cureX AB (publ) | -32.51 Million SEK | 49.32% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -28.469% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.465% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.019% |
| Biosergen AB | -27.03 Million SEK | 39.046% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 0.26% |
| Corline Biomedical AB | -1.8 Million SEK | -811.001% |
| NextCell Pharma AB | -41.95 Million SEK | 60.724% |
| Nanologica AB (publ) | -75.15 Million SEK | 78.073% |
| LIDDS AB (publ) | -40.2 Million SEK | 59.011% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 94.959% |
| BioInvent International AB (publ) | -330.3 Million SEK | 95.011% |
| SynAct Pharma AB | -215.81 Million SEK | 92.364% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 62.591% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 30.573% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 84.921% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 93.384% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -65.962% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 85.457% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 21.862% |
| Simris Alg AB (publ) | -37.3 Million SEK | 55.824% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 89.147% |